COX18

Across TCGA pan-cancer cohorts, COX18 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated COX18 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher COX18 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated COX18 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where COX18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.475	1.000	.036	10	view →
PDAC	DFS	Median	All	0.222	0.605	.024	5	view →
LSCC	DFS	Median	II,III,IV	1.000	0.507	.032	2	view →
UCEC	DFS	Median	All	0.928	1.000	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

COX18–HNSC (DFS)

Open the HNSC breakdown →